|Bid||5.06 x 317000|
|Ask||0.00 x 42300|
|Day's Range||5.84 - 5.85|
|52 Week Range||5.84 - 5.85|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Biotech stocks have had a fairly good outing so far in 2019 after generating negative returns in 2018. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB ) clocked a gain of 15.94 percent for the March ...
Merck (MRK) to buy Immune Design for $300 million. FDA grants priority review to regulatory applications filed by Merck, Roche (RHHBY) and AbbVie (ABBV).
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 21.) Eli Lilly And Co (NYSE: LLY ) Gossamer ...
Dow Jones component Merck, in an effort to bolster its vaccine offerings, will spend $300 million to buy Immune Design. Immune Design stock flew more than 300% as Merck rose a fraction.
Biotech M&A is on a roll in 2019, with a couple of multi-billion dollar deals announced already, including Bristol-Myers Squibb Co (NYSE: BMY )'s proposed buy of Celgene Corporation (NASDAQ: CELG ) and ...
Merck & Co Inc said on Thursday it would buy drug developer Immune Design Corp for nearly $300 million, to gain access to its immunotherapy programs. Merck will pay $5.85 in cash for each share of Immune ...
The direct benefit for Immune Design Corp. (NASDAQ:IMDZ), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off Read More...
Immune Design (IMDZ) posts narrower-than-expected loss and misses revenue estimates in the third quarter of 2018. It expects to have cash to fund operations in 2021.
Immune Design (IMDZ) delivered earnings and revenue surprises of 9.38% and -37.99%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Seattle-based company said it had a loss of 29 cents per share. The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss ...
The layoffs amount to about 20 percent of Immune Design's workforce in Seattle and South San Francisco.
The layoffs amount to about 20 percent of Immune Design's workforce in Seattle and San Francisco.
Immune Design's stock price dropped more than 30 percent on the decision, which pushes the prospects of FDA approval several years into the future.
Here's a roundup of top developments in the biotech space over the last 24 hours. Amid the market mayhem, no biotech or medical device companies made it to 52-week highs. Down In The Dumps (Biotech stocks ...
The big shareholder groups in Immune Design Corp (NASDAQ:IMDZ) have power over the company. Institutions often own shares in more established companies, while it’s not unusual to see insiders own Read More...
Immune Design Corp (NASDAQ:IMDZ), a US$183.0m small-cap, is a healthcare company operating in an industry, which continues to be affected by the sustained economic uncertainty and structural trends, such asRead More...
Immune Design (IMDZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.